Other
HER2 Positive
0
Pipeline Programs↗
9
Active Trials↗
7
Companies Involved↗
HER2 Positive is an early-stage landscape with 0 programs across 7 companies. The most active players are Merrimack Pharmaceuticals, Bristol-Myers Squibb, Pfizer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
32
clinical trials
Completed10 · 31%
Unknown status7 · 22%
Terminated4 · 13%
Recruiting3 · 9%
Active, not recruiting3 · 9%
Withdrawn2 · 6%
Other3 · 9%
Clinical Trials
Trial Activity
32 trials
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Recruiting·—·Phase 1·NCT03740256·45 enrolled
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Active, not recruiting·—·Phase 1·NCT03716180·100 enrolled
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
Active, not recruiting·—·Phase 1·NCT02442297·10 enrolled
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
Not yet recruiting·—·Phase 2·NCT07243938·70 enrolled
The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
Enrolling by invitation·—·Phase 1·NCT07023861·20 enrolled
Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy
Completed·—·Phase 1·NCT00889954·20 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)